Medical device according to EU MDR 2017/745
Your instant decision support
Utilize Dermalyser app with AI analysis for an accurate second opinion when evaluating skin lesions. A decision support designed for all medical professionals dealing with skin lesions.
Intuitive
Fast
Accurate
Three simple steps
To get a second opinion in seconds
Start Dermalyser in any smartphone
Get an account by contacting us
Take a photo of the lesion with the app
Applicable with most dermatoscopes
Get immediate analysis
Diagnostic decision always stays with you as a doctor
When clinically validated and responsibly implemented, AI can play an important role in improving access to high-quality skin cancer assessment while supporting appropriate referral pathways.
Professor Josep Malvehy
Who is Dermalyser for?
Dermalyser is a decision support for licensed healthcare professionals, such as primary care physicians, dermatologists and general practitioners.
Primary Care
Dermatology Clinics
Hospitals
Longevity Clinics
Family Medicine
Health Care Systems
Workplace Health Services
Occupational Health
Primary Care Physicians
General Practitioners
Dermatologists
Medical professionals can enhance their practice with Dermalyser, utilizing its clinically validated AI technique for highly accurate skin lesion diagnostics. This allows precise evaluations, minimizing false positives and avoiding unnecessary treatments, leading to quicker and more accurate assessments.
Accurate assessments (AUC)
Dermalyser
Expert Dermatologist
General Practitioner
Instant Decision Support
Proven results in real clinical settings
Data from clinical studies show that Dermalyser exceed both dermatologists and general practitioners in correct assessments of skin lesions.
Trusted by leading dermatologists
AI is here to support you, not replace you. Developed in close collaboration with dermatologists and primary care physicians.
96% AUC
Clinically validated AI technique provides exceptional precision in skin lesion diagnostics.
56% Cost Savings
Less time per patient and no need for waiting on external experts' second opinion.
79% Fewer Referrals
More accurate assessments lead to fewer false positives and reduced overtreatment.
5 Sec Analysis
Immediate feedback during consultation, no waiting for results.
99.8 NPV
High confidence (Negative Predictive Value) in ruling out malignancy when a lesion is assessed as benign.
100% Doctors Decision
Dermalyser is an assistant, not a replacement. You always have the final word in diagnosis.
* Results reflect findings from Clinical Studies
Actual outcomes may vary depending on clinical workflow and implementation context.
Enhanced Patient Safety
Faster and more confident decisions at the point of care
Dermalyser is a CE-marked app that provides
AI-driven decision support in seconds, by analysing a dermascopic image captured with your smartphone.
Clinical costs savings
50%
With Dermalyser
Up to 50% Cost Reduction
Reduce clinical costs
Studies show that Dermalyser can reduce costs by up to 56%. Improved patient flow, reduced referrals, and fewer excisions. Decrease patient overload while boosting confidence in every diagnosis.
DermAIM Results In An Integrated Host System
DermAIM - AI decision support for healthcare platforms
DermAIM is an AI engine delivered via secure APIs, designed for healthcare system vendors who need clinically validated skin lesion risk assessment.
Quick answers to common questions
Dermalyser is a CE-marked software that uses artificial intelligence to analyze digital dermatoscopic images of skin lesions. It functions as a decision-support tool for healthcare professionals when assessing suspected skin melanomas.
Only licenced healthcare professionals, such as general practitioners, primary care physicians, and dermatologists.
No. Dermalyser is a decision-support tool. The final diagnosis is always made by healthcare professionals.
A smartphone with the Dermalyser app, a compatible dermatoscope, and a clinical environment with trained healthcare staff.
Dermalyser has been validated for patients with Fitzpatrick skin types I–IV.
No. Dermalyser is intended for suspected melanomas. It should not be used on ulcerated or open lesions, very large lesions, lesions on mucous membranes, under nails, on palms or soles, near the eyes, or on lesions that have already been biopsied.
An analysis typically takes only a few seconds once the image is captured.
See how Dermalyser works yourself
Discover how Dermalyser could increase your clinical confidence.
Book a Demo